The discovery of robust antidepressant actions exerted by the N-methyl-D-aspartate receptor
(NMDAR) antagonist (R, S)-ketamine has been a crucial breakthrough in mood disorder …

Ketamine, a racemic mixture consisting of (S)-and (R)-ketamine, has been in clinical use
since 1970. Although best characterized for its dissociative anesthetic properties, ketamine …

Abstract Treatment outcomes for major depressive disorder (MDD) need to be improved.
Presently, no clinically relevant tools have been established for stratifying subgroups or …

Ketamine, an N-methyl-d-aspartate receptor (NMDAR) antagonist first developed as an
anesthetic, has shown significant promise as a medication with rapid antidepressant …

Major depressive disorder (MDD) is one of the most disabling psychiatric disorders.
Approximately one‐third of the patients with MDD are treatment resistant to the current …

Major Depressive Disorder (MDD) is a leading cause of disability worldwide, creating a high
medical and socioeconomic burden. There is a growing interest in the biological …

Twenty-four hours after administration, ketamine exerts rapid and robust antidepressant
effects that are thought to be mediated by activation of the mechanistic target of rapamycin …

Highlights•Chronic stress, depression and inflammation have been consistently
linked.•Stress-induced inflammatory states can contribute to treatment resistance.•Ketamine …

Neurological disorders are the leading cause of disability and the second leading cause of
death worldwide. The increasing social and economic burdens of neurological disorders are …

Introduction: Depression is one of the most disabling diseases worldwide. Approximately
one-third of depressed patients are treatment-resistant to the currently available …